Latham & Watkins Advises Leerink Partners on Immunovant US$550 Million Common Stock Offering

"Latham & Watkins advised underwriter Leerink Partners on Immunovant, Inc.'s underwritten offering of 26.2 million common shares at US$21 per share, expected to raise approximately US$550 million gross. The transaction is expected to close on or about December 12, 2025, subject to customary closing conditions."

Latham & Watkins LLP represented Leerink Partners, the underwriter, in connection with Immunovant, Inc.'s common stock offering. Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, announced the pricing of an underwritten offering of its common stock. Immunovant offered 26.2 million shares at an offering price of US$21 per share, with anticipated gross proceeds to the company of approximately US$550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. The offering is expected to close on or about December 12, 2025, subject to the satisfaction of customary closing conditions. Latham & Watkins LLP represented Leerink Partners with a Capital Markets team composed by: New York partners Nathan Ajiashvili and Salvatore Vanchieri, and associates Kaj Nielsen, Jie Lin Nai, Kan Ni, and Sean Kim.

Latham & Watkins Advises Leerink Partners on Immunovant US$550 Million Common Stock Offering

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads